BRIDGEWATER, NJ — March 15, 2002 — Two studies published today in the Journal of Clinical Oncology (JCO) showed promising response rates in patients treated with Taxotere® (docetaxel) for Injection Concentrate. These studies demonstrate the potential benefit of Taxotere-based therapy over existing therapies in treating several types of cancer.
Findings of a breast cancer study published today in JCO support the addition of Taxotere in neo-adjuvant (prior to surgery) chemotherapy for the treatment of breast cancer. In a study of women with large (3 cm or more) or locally advanced breast cancer, patients given Taxotere following anthracycline-based chemotherapy experienced a better response rate in reduction in the size or disappearance of the tumor than those patients given the anthracycline-based regimen alone. Treatment with an anthracycline-based chemotherapy regimen is currently a standard of care in the neo-adjuvant setting.
The study, conducted at the University of Aberdeen in the UK, found that patients who responded to four cycles of neo-adjuvant chemotherapy with an anthracycline-based regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CVAP) and followed by four cycles of Taxotere, experienced a higher clinical response rate (94 percent vs. 66 percent) and a higher complete pathological response rate (34 percent vs. 16 percent) than those patients given four additional cycles of the anthracycline regimen. A clinical response refers to the physically observable disappearance or shrinkage of a tumor; a pathological response refers to the microscopic analysis of breast tissue.